Makary’s Hammer: FDA Signals the End of the GLP-1 ‘Shortage Arbitrage’ Era
On Feb 6, 2026, the FDA moved to curb GLP-1 APIs in mass-marketed unapproved compounded drugs, reinforcing safeguards for major players like Novo Nordisk amid easing shortages.
Read More